TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of Ticagrelor Compared With Clopidogrel for Prevention of Vascular Events in Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS) [PLATO- a Study of PLATelet Inhibition and Patient Outcomes]
Brief Summary: Ticagrelor is a new, reversible binding, anti-platelet medication. Anti-platelet medications work to prevent the formation of blood clots. Ticagrelor is being developed as a treatment for patients with acute coronary syndrome (ACS). ACS is a term that is used to describe both heart attacks in progress or the imminent threat of a heart attack. ACS is usually caused by the formation of a blood clot in an artery that partially or totally blocks the blood supply to a portion of the heart muscle. Ticagrelor will be compared with clopidogrel to determine which drug, when either is used in conjunction with aspirin, is better at reducing deaths from vascular causes, future heart attacks and/or strokes in patients with ACS.


Options:
A: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Enoxaparin/VKA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin followed by VKA | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Enoxaparin followed by VKA; Assigned to Arm(s): Enoxaparin/VKA
B: Arm Label: Clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Arm Label: Ticagrelor; Type: EXPERIMENTAL; Interventions: Drug: Ticagrelor | Intervention Type: DRUG; Name: Ticagrelor; Assigned to Arm(s): Ticagrelor | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Clopidogrel
C: Intervention Type: DRUG; Name: clopidogrel (SR25990C); Assigned to Arm(s): N/A
D: Arm Label: dabigatran etexilate 150 mg; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate 150 mg | Arm Label: warfarin (INR 2-3); Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin (INR 2-3) | Intervention Type: DRUG; Name: dabigatran etexilate 150 mg; Assigned to Arm(s): dabigatran etexilate 150 mg | Intervention Type: DRUG; Name: warfarin (INR 2-3); Assigned to Arm(s): warfarin (INR 2-3)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Microbiologic Efficacy and Safety of Two Treatment Regimens of Inhaled Tobramycin Nebuliser Solution (TNS) for the Treatment of Early Onset Pseudomonas Aeruginosa Lower Respiratory Tract Infection in Subjects With Cystic Fibrosis
Brief Summary: This study assessed time to recurrence of infection with Pseudomonas aeruginosa following treatment of the initial infection with tobramycin nebuliser solution. The safety profile of the initial tobramycin treatment was assessed during the first 3 months of the study and patients were followed until the end of the study, month 27.


Options:
A: Arm Label: Placebo (pooled two times a day [BID]/three times a day [TID]); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo two times a day (BID)/three times a day (TID) | Arm Label: AZLI (pooled two times a day [BID]/three times a day [TID]); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg two times a day (BID)/three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg two times a day (BID)/three times a day (TID); Assigned to Arm(s): AZLI (pooled two times a day [BID]/three times a day [TID]) | Intervention Type: DRUG; Name: Placebo two times a day (BID)/three times a day (TID); Assigned to Arm(s): Placebo (pooled two times a day [BID]/three times a day [TID])
B: Arm Label: Aeroquin 240 mg; Type: EXPERIMENTAL; Interventions: Drug: Aeroquin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aeroquin; Assigned to Arm(s): Aeroquin 240 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo three times daily (TID); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo three times daily (TID) | Arm Label: AZLI 75 mg three times daily (TID); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg three times daily (TID) | Intervention Type: DRUG; Name: AZLI 75 mg three times daily (TID); Assigned to Arm(s): AZLI 75 mg three times daily (TID) | Intervention Type: DRUG; Name: Placebo three times daily (TID); Assigned to Arm(s): Placebo three times daily (TID)
D: Arm Label: Tobramycin 300 mg for 28 days; Type: EXPERIMENTAL; Interventions: Drug: Tobramycin solution for inhalation 300 mg | Arm Label: Tobramycin 300 mg for 56 days; Type: EXPERIMENTAL; Interventions: Drug: Tobramycin solution for inhalation 300 mg | Intervention Type: DRUG; Name: Tobramycin solution for inhalation 300 mg; Assigned to Arm(s): Tobramycin 300 mg for 28 days, Tobramycin 300 mg for 56 days

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Microbiologic Efficacy and Safety of Two Treatment Regimens of Inhaled Tobramycin Nebuliser Solution (TNS) for the Treatment of Early Onset Pseudomonas Aeruginosa Lower Respiratory Tract Infection in Subjects With Cystic Fibrosis
Brief Summary: This study assessed time to recurrence of infection with Pseudomonas aeruginosa following treatment of the initial infection with tobramycin nebuliser solution. The safety profile of the initial tobramycin treatment was assessed during the first 3 months of the study and patients were followed until the end of the study, month 27.


Options:
A: Arm Label: Bramitob; Type: EXPERIMENTAL; Interventions: Drug: tobramycin / Bramitob | Arm Label: TOBI; Type: ACTIVE_COMPARATOR; Interventions: Drug: tobramycin / TOBI | Intervention Type: DRUG; Name: tobramycin / Bramitob; Assigned to Arm(s): Bramitob | Intervention Type: DRUG; Name: tobramycin / TOBI; Assigned to Arm(s): TOBI
B: Arm Label: Tobramycin 300 mg for 28 days; Type: EXPERIMENTAL; Interventions: Drug: Tobramycin solution for inhalation 300 mg | Arm Label: Tobramycin 300 mg for 56 days; Type: EXPERIMENTAL; Interventions: Drug: Tobramycin solution for inhalation 300 mg | Intervention Type: DRUG; Name: Tobramycin solution for inhalation 300 mg; Assigned to Arm(s): Tobramycin 300 mg for 28 days, Tobramycin 300 mg for 56 days
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: MP-376 120 mg QD; Type: EXPERIMENTAL; Interventions: Drug: MP-376 | Arm Label: MP-376 240 mg QD; Type: EXPERIMENTAL; Interventions: Drug: MP-376 | Arm Label: MP-376 240 mg BID; Type: EXPERIMENTAL; Interventions: Drug: MP-376 | Intervention Type: DRUG; Name: MP-376; Assigned to Arm(s): MP-376 120 mg QD, MP-376 240 mg BID, MP-376 240 mg QD | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo three times a day (TID); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo three times a day (TID) | Arm Label: AZLI 75 mg three times a day (TID); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg three times a day (TID); Assigned to Arm(s): AZLI 75 mg three times a day (TID) | Intervention Type: DRUG; Name: Placebo three times a day (TID); Assigned to Arm(s): Placebo three times a day (TID)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Microbiologic Efficacy and Safety of Two Treatment Regimens of Inhaled Tobramycin Nebuliser Solution (TNS) for the Treatment of Early Onset Pseudomonas Aeruginosa Lower Respiratory Tract Infection in Subjects With Cystic Fibrosis
Brief Summary: This study assessed time to recurrence of infection with Pseudomonas aeruginosa following treatment of the initial infection with tobramycin nebuliser solution. The safety profile of the initial tobramycin treatment was assessed during the first 3 months of the study and patients were followed until the end of the study, month 27.


Options:
A: Arm Label: Tobramycin 300 mg for 28 days; Type: EXPERIMENTAL; Interventions: Drug: Tobramycin solution for inhalation 300 mg | Arm Label: Tobramycin 300 mg for 56 days; Type: EXPERIMENTAL; Interventions: Drug: Tobramycin solution for inhalation 300 mg | Intervention Type: DRUG; Name: Tobramycin solution for inhalation 300 mg; Assigned to Arm(s): Tobramycin 300 mg for 28 days, Tobramycin 300 mg for 56 days
B: Arm Label: Cohort 1 - 280 mg ARIKACE™; Type: EXPERIMENTAL; Interventions: Drug: ARIKACE™ | Arm Label: Cohort 1 - Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cohort 2 - 560 mg ARIKACE™; Type: EXPERIMENTAL; Interventions: Drug: ARIKACE™ | Arm Label: Cohort 2 - Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ARIKACE™; Assigned to Arm(s): Cohort 1 - 280 mg ARIKACE™, Cohort 2 - 560 mg ARIKACE™ | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1 - Placebo, Cohort 2 - Placebo
C: Arm Label: CF patients with pulmonary exacerbations; Type: N/A; Interventions: N/A
D: Arm Label: Aeroquin 240 mg; Type: EXPERIMENTAL; Interventions: Drug: Aeroquin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aeroquin; Assigned to Arm(s): Aeroquin 240 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Microbiologic Efficacy and Safety of Two Treatment Regimens of Inhaled Tobramycin Nebuliser Solution (TNS) for the Treatment of Early Onset Pseudomonas Aeruginosa Lower Respiratory Tract Infection in Subjects With Cystic Fibrosis
Brief Summary: This study assessed time to recurrence of infection with Pseudomonas aeruginosa following treatment of the initial infection with tobramycin nebuliser solution. The safety profile of the initial tobramycin treatment was assessed during the first 3 months of the study and patients were followed until the end of the study, month 27.


Options:
A: Arm Label: Observational; Type: N/A; Interventions: N/A
B: Arm Label: TOBI (tobramycin inhaled solution)/Placebo; Type: EXPERIMENTAL; Interventions: Drug: TOBI, Drug: Placebo | Arm Label: Placebo/TOBI; Type: PLACEBO_COMPARATOR; Interventions: Drug: TOBI, Drug: Placebo | Intervention Type: DRUG; Name: TOBI; Assigned to Arm(s): Placebo/TOBI, TOBI (tobramycin inhaled solution)/Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/TOBI, TOBI (tobramycin inhaled solution)/Placebo
C: Arm Label: Placebo (pooled two times a day [BID]/three times a day [TID]); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo two times a day (BID)/three times a day (TID) | Arm Label: AZLI (pooled two times a day [BID]/three times a day [TID]); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg two times a day (BID)/three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg two times a day (BID)/three times a day (TID); Assigned to Arm(s): AZLI (pooled two times a day [BID]/three times a day [TID]) | Intervention Type: DRUG; Name: Placebo two times a day (BID)/three times a day (TID); Assigned to Arm(s): Placebo (pooled two times a day [BID]/three times a day [TID])
D: Arm Label: Tobramycin 300 mg for 28 days; Type: EXPERIMENTAL; Interventions: Drug: Tobramycin solution for inhalation 300 mg | Arm Label: Tobramycin 300 mg for 56 days; Type: EXPERIMENTAL; Interventions: Drug: Tobramycin solution for inhalation 300 mg | Intervention Type: DRUG; Name: Tobramycin solution for inhalation 300 mg; Assigned to Arm(s): Tobramycin 300 mg for 28 days, Tobramycin 300 mg for 56 days

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Microbiologic Efficacy and Safety of Two Treatment Regimens of Inhaled Tobramycin Nebuliser Solution (TNS) for the Treatment of Early Onset Pseudomonas Aeruginosa Lower Respiratory Tract Infection in Subjects With Cystic Fibrosis
Brief Summary: This study assessed time to recurrence of infection with Pseudomonas aeruginosa following treatment of the initial infection with tobramycin nebuliser solution. The safety profile of the initial tobramycin treatment was assessed during the first 3 months of the study and patients were followed until the end of the study, month 27.


Options:
A: Arm Label: AZLI then Standard Care; Type: EXPERIMENTAL; Interventions: Drug: Aztreonam, Drug: Standard Care | Arm Label: Standard Care then AZLI; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aztreonam, Drug: Standard Care | Intervention Type: DRUG; Name: Aztreonam; Assigned to Arm(s): AZLI then Standard Care, Standard Care then AZLI | Intervention Type: DRUG; Name: Standard Care; Assigned to Arm(s): AZLI then Standard Care, Standard Care then AZLI
B: Arm Label: Tobramycin 300 mg for 28 days; Type: EXPERIMENTAL; Interventions: Drug: Tobramycin solution for inhalation 300 mg | Arm Label: Tobramycin 300 mg for 56 days; Type: EXPERIMENTAL; Interventions: Drug: Tobramycin solution for inhalation 300 mg | Intervention Type: DRUG; Name: Tobramycin solution for inhalation 300 mg; Assigned to Arm(s): Tobramycin 300 mg for 28 days, Tobramycin 300 mg for 56 days
C: Arm Label: AZLI; Type: ACTIVE_COMPARATOR; Interventions: Drug: AZLI, Drug: Tobramycin inhalation solution | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to match AZLI, Drug: Tobramycin inhalation solution | Intervention Type: DRUG; Name: AZLI; Assigned to Arm(s): AZLI | Intervention Type: DRUG; Name: Placebo to match AZLI; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Tobramycin inhalation solution; Assigned to Arm(s): AZLI, Placebo
D: Arm Label: CF patients with pulmonary exacerbations; Type: N/A; Interventions: N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Microbiologic Efficacy and Safety of Two Treatment Regimens of Inhaled Tobramycin Nebuliser Solution (TNS) for the Treatment of Early Onset Pseudomonas Aeruginosa Lower Respiratory Tract Infection in Subjects With Cystic Fibrosis
Brief Summary: This study assessed time to recurrence of infection with Pseudomonas aeruginosa following treatment of the initial infection with tobramycin nebuliser solution. The safety profile of the initial tobramycin treatment was assessed during the first 3 months of the study and patients were followed until the end of the study, month 27.


Options:
A: Arm Label: Placebo (pooled two times a day [BID]/three times a day [TID]); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo two times a day (BID)/three times a day (TID) | Arm Label: AZLI (pooled two times a day [BID]/three times a day [TID]); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg two times a day (BID)/three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg two times a day (BID)/three times a day (TID); Assigned to Arm(s): AZLI (pooled two times a day [BID]/three times a day [TID]) | Intervention Type: DRUG; Name: Placebo two times a day (BID)/three times a day (TID); Assigned to Arm(s): Placebo (pooled two times a day [BID]/three times a day [TID])
B: Arm Label: Placebo three times daily (TID); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo three times daily (TID) | Arm Label: AZLI 75 mg three times daily (TID); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg three times daily (TID) | Intervention Type: DRUG; Name: AZLI 75 mg three times daily (TID); Assigned to Arm(s): AZLI 75 mg three times daily (TID) | Intervention Type: DRUG; Name: Placebo three times daily (TID); Assigned to Arm(s): Placebo three times daily (TID)
C: Arm Label: Tobramycin 300 mg for 28 days; Type: EXPERIMENTAL; Interventions: Drug: Tobramycin solution for inhalation 300 mg | Arm Label: Tobramycin 300 mg for 56 days; Type: EXPERIMENTAL; Interventions: Drug: Tobramycin solution for inhalation 300 mg | Intervention Type: DRUG; Name: Tobramycin solution for inhalation 300 mg; Assigned to Arm(s): Tobramycin 300 mg for 28 days, Tobramycin 300 mg for 56 days
D: Arm Label: AZLI; Type: ACTIVE_COMPARATOR; Interventions: Drug: AZLI, Drug: Tobramycin inhalation solution | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to match AZLI, Drug: Tobramycin inhalation solution | Intervention Type: DRUG; Name: AZLI; Assigned to Arm(s): AZLI | Intervention Type: DRUG; Name: Placebo to match AZLI; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Tobramycin inhalation solution; Assigned to Arm(s): AZLI, Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Microbiologic Efficacy and Safety of Two Treatment Regimens of Inhaled Tobramycin Nebuliser Solution (TNS) for the Treatment of Early Onset Pseudomonas Aeruginosa Lower Respiratory Tract Infection in Subjects With Cystic Fibrosis
Brief Summary: This study assessed time to recurrence of infection with Pseudomonas aeruginosa following treatment of the initial infection with tobramycin nebuliser solution. The safety profile of the initial tobramycin treatment was assessed during the first 3 months of the study and patients were followed until the end of the study, month 27.


Options:
A: Arm Label: 32.50 mg Ciprofloxacin DPI (BAYQ3939); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin (Cipro Inhale, BAYQ3939) | Arm Label: 48.75 mg Ciprofloxacin DPI (BAYQ3939); Type: EXPERIMENTAL; Interventions: Drug: Ciprofloxacin (Cipro Inhale, BAYQ3939) | Arm Label: Matching Placebo for 32.50 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Matching Placebo for 48.75 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ciprofloxacin (Cipro Inhale, BAYQ3939); Assigned to Arm(s): 32.50 mg Ciprofloxacin DPI (BAYQ3939) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Matching Placebo for 32.50 mg | Intervention Type: DRUG; Name: Ciprofloxacin (Cipro Inhale, BAYQ3939); Assigned to Arm(s): 48.75 mg Ciprofloxacin DPI (BAYQ3939) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Matching Placebo for 48.75 mg
B: Arm Label: Tobramycin 300 mg for 28 days; Type: EXPERIMENTAL; Interventions: Drug: Tobramycin solution for inhalation 300 mg | Arm Label: Tobramycin 300 mg for 56 days; Type: EXPERIMENTAL; Interventions: Drug: Tobramycin solution for inhalation 300 mg | Intervention Type: DRUG; Name: Tobramycin solution for inhalation 300 mg; Assigned to Arm(s): Tobramycin 300 mg for 28 days, Tobramycin 300 mg for 56 days
C: Intervention Type: DRUG; Name: tobramycin; Assigned to Arm(s): N/A
D: Arm Label: Placebo (pooled two times a day [BID]/three times a day [TID]); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo two times a day (BID)/three times a day (TID) | Arm Label: AZLI (pooled two times a day [BID]/three times a day [TID]); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg two times a day (BID)/three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg two times a day (BID)/three times a day (TID); Assigned to Arm(s): AZLI (pooled two times a day [BID]/three times a day [TID]) | Intervention Type: DRUG; Name: Placebo two times a day (BID)/three times a day (TID); Assigned to Arm(s): Placebo (pooled two times a day [BID]/three times a day [TID])

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: First Line Radiofrequency Ablation Versus Antiarrhythmic Drugs for Atrial Fibrillation Treatment: A Multi-center Randomized Trial
Brief Summary: The purpose of this study is to determine whether catheter-based pulmonary vein isolation is superior to antiarrhythmic drugs as first line therapy in patients with symptomatic paroxysmal recurrent atrial fibrillation not previously treated with therapeutic doses of antiarrhythmic drugs.


Options:
A: N/A
B: Arm Label: NAVISTAR® THERMOCOOL® Catheter; Type: EXPERIMENTAL; Interventions: Device: NAVISTAR® THERMOCOOL® Catheter | Arm Label: Antiarrhythmic drug; Type: ACTIVE_COMPARATOR; Interventions: Drug: Antiarrhythmic drug | Intervention Type: DEVICE; Name: NAVISTAR® THERMOCOOL® Catheter; Assigned to Arm(s): NAVISTAR® THERMOCOOL® Catheter | Intervention Type: DRUG; Name: Antiarrhythmic drug; Assigned to Arm(s): Antiarrhythmic drug
C: Arm Label: Catheter Ablation; Type: EXPERIMENTAL; Interventions: Procedure: Pulmonary Vein Isolation performed by Catheter Ablation | Arm Label: Antiarrhythmic Drug Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Conventional Antiarrhythmic Drug Therapy | Intervention Type: PROCEDURE; Name: Pulmonary Vein Isolation performed by Catheter Ablation; Assigned to Arm(s): Catheter Ablation | Intervention Type: DRUG; Name: Conventional Antiarrhythmic Drug Therapy; Assigned to Arm(s): Antiarrhythmic Drug Therapy
D: Arm Label: Drug Treatment; Type: ACTIVE_COMPARATOR; Interventions: Device: Radiofrequency ablation, antiarrhythmic drugs, Drug: Amiodarone, flecainide, propafenone, quinidine, dofetilide, sotalol, cibenzoline, beta blocking and calcium channel blocking agents and antiarrhythmic drugs | Arm Label: ThermoCool Radiofrequency Catheter; Type: ACTIVE_COMPARATOR; Interventions: Device: Radiofrequency ablation, antiarrhythmic drugs, Device: ThermoCool Radiofrequency Catheter | Intervention Type: DEVICE; Name: Radiofrequency ablation, antiarrhythmic drugs; Assigned to Arm(s): Drug Treatment, ThermoCool Radiofrequency Catheter | Intervention Type: DRUG; Name: Amiodarone, flecainide, propafenone, quinidine, dofetilide, sotalol, cibenzoline, beta blocking and calcium channel blocking agents and antiarrhythmic drugs; Assigned to Arm(s): Drug Treatment | Intervention Type: DEVICE; Name: ThermoCool Radiofrequency Catheter; Assigned to Arm(s): ThermoCool Radiofrequency Catheter

Answer: C